# Report

## **Monthly New Drug and First Time Generic** August 2021



### **New Brand Drug Pipeline**

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Celecoxib Oral Liquid ( <b>Elyxyb</b> ™)	NSAID	Migraine Headache Treatment	Launch pending. Approved May 5, 2020.
Benzhydrocodone HCl/ Acetaminophen ( <b>Apadaz</b> ™)	Opioid Analgesic – Immediate Release	Pain	Launch pending. Approved February 23, 2018.
Buprenorphine Depot Injection ( <b>Brixadi™</b> )	Opioid Agonist	Treatment of Opioid Addiction	FDA review pending.
Celecoxib/Tramadol	NSAID/Opioid Agonist	Pain	FDA review pending.
Oxycodone ( <b>Aximris XR™</b> )	Opioid Analgesic – Extended Release	Pain	FDA review pending.
Ansofaxine	Antidepressant	Major Depressive Disorder	FDA review pending.
Nalmefene Injection	Opioid Antagonist	Opioid Overdose	FDA review pending.
Naloxone Injection ( <b>Zimhi™</b> )	Opioid Antagonist	Opioid Overdose	FDA review pending.

### **Generic Pipeline**

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Dabigatran ( <b>Pradaxa</b> ®)	Anticoagulant	Treatment/ Prophylaxis of Deep Vein Thrombosis	First patent set to expire December 2021. Generic anticipated June 2022.
Oxycodone HCl ( <b>Oxaydo</b> ®)	Opioid Agonist	Pain	Generic exclusivity anticipated in 2022.
Apixaban ( <b>Eliquis</b> ®)	Anticoagulant	Treatment/ Prophylaxis of Deep Vein Thrombosis	Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.
Naloxone HCl <b>(Narcan®</b> ) Nasal Spray	Opioid Antagonist	Opioid Overdose	Launch pending. Generic approved April 19, 2019.

# Report

## **Monthly New Drug and First Time Generic** August 2021



#### **Available in the Last 12 Months**

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Naloxone Nasal Spray ( <b>Kloxxado™</b> )	Opioid Antagonist	Opioid Overdose	August 2021
Oliceridine ( <b>Olinvyk™</b> ) Injection	Opioid Agonist	Pain	November 2020
Tramadol Oral Solution ( <b>Qdolo™</b> )	Opioid Agonist	Pain	October 2020
Newly Available Generics			
Ibuprofen/Famotidine ( <b>Duexis</b> ®)	NSAID/H-2 Receptor Antagonist	Pain/Inflammation	August 2021
Pregabalin Extended Release ( <b>Lyrica</b> <sup>®</sup> <b>CR</b> )	Anticonvulsant	Neuropathic Pain	April 2021
Hydrocodone Bitartrate ( <b>Hysingla™ ER</b> )	Opioid Agonist – Extended Release	Pain	March 2021
Topiramate ER Capsule ( <b>Qudexy</b> ® <b>XR</b> )	Anticonvulsant	Headache, Neuro- pathic Pain	February 2021
Emtricitabine/Tenofovir ( <b>Truvada</b> ®)	Antiretroviral	HIV Post-Exposure Prophylaxis	January 2021
Meloxicam ( <b>Vivlodex</b> ®)	NSAID	Pain	December 2020

#### **Discontinuations & Withdrawals**

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Naloxone HCl ( <b>Evzio</b> ®)	Opioid Antagonist	Opioid Overdose	The manufacturer made a business decision to discontinue in September 2020.